{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:38:00Z","timestamp":1775151480850,"version":"3.50.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"17-18","license":[{"start":{"date-parts":[[2010,8,16]],"date-time":"2010-08-16T00:00:00Z","timestamp":1281916800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s10354-010-0818-x","type":"journal-article","created":{"date-parts":[[2010,8,16]],"date-time":"2010-08-16T08:52:48Z","timestamp":1281948768000},"page":"452-457","source":"Crossref","is-referenced-by-count":39,"title":["Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: Are they of any help?","Osteoprotegerin (OPG) und Receptor Activator for Nuclear Factor kappaB Ligand (RANKL) Bestimmung im Serum: Sinn oder Unsinn?"],"prefix":"10.1007","volume":"160","author":[{"given":"Doris","family":"Wagner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Fahrleitner-Pammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,16]]},"reference":[{"issue":"2","key":"818_CR1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 89(2): 309\u2013319, 1997","journal-title":"Cell"},{"issue":"3","key":"818_CR2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1210\/endo.139.3.5837","volume":"139","author":"H Yasuda","year":"1998","unstructured":"Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG\/OCIF inhibits osteoclastogenesis in vitro. Endocrinology, 139(3): 1329\u20131337, 1998","journal-title":"Endocrinology"},{"issue":"7","key":"818_CR3","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","volume":"95","author":"H Yasuda","year":"1998","unstructured":"Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL. Proc Natl Acad Sci USA, 95(7): 3597\u20133602, 1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6759","key":"818_CR4","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/46303","volume":"402","author":"YY Kong","year":"1999","unstructured":"Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature, 402(6759): 304\u2013309, 1999","journal-title":"Nature"},{"issue":"2","key":"818_CR5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93(2): 165\u2013176, 1998","journal-title":"Cell"},{"issue":"6656","key":"818_CR6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/36593","volume":"390","author":"DM Anderson","year":"1997","unstructured":"Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature, 390(6656): 175\u2013179, 1997","journal-title":"Nature"},{"issue":"7","key":"818_CR7","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","volume":"96","author":"H Hsu","year":"1999","unstructured":"Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA, 96(7): 3540\u20133545, 1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"818_CR8","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1084\/jem.188.5.997","volume":"188","author":"K Fuller","year":"1998","unstructured":"Fuller K, Wong B, Fox S, et al. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med, 188(5): 997\u20131001, 1998","journal-title":"J Exp Med"},{"issue":"10","key":"818_CR9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0167-5699(00)01718-7","volume":"21","author":"YY Kong","year":"2000","unstructured":"Kong YY, Boyle WJ, Penninger JM. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today, 21(10): 495\u2013502, 2000","journal-title":"Immunol Today"},{"issue":"3","key":"818_CR10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/eje.0.1410195","volume":"141","author":"LC Hofbauer","year":"1999","unstructured":"Hofbauer LC. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Eur J Endocrinol, 141(3): 195\u2013210, 1999","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"818_CR11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1359\/jbmr.2000.15.1.2","volume":"15","author":"LC Hofbauer","year":"2000","unstructured":"Hofbauer LC, Khosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res, 15(1): 2\u201312, 2000","journal-title":"J Bone Miner Res"},{"issue":"9","key":"818_CR12","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","volume":"12","author":"N Bucay","year":"1998","unstructured":"Bucay N, Sarosi I, Dunstan CR, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev, 12(9): 1260\u20131268, 1998","journal-title":"Genes Dev"},{"issue":"3","key":"818_CR13","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1006\/bbrc.1998.8697","volume":"247","author":"A Mizuno","year":"1998","unstructured":"Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor\/osteoprotegerin. Biochem Biophys Res Commun, 247(3): 610\u2013615, 1998","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"818_CR14","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1359\/jbmr.2001.16.2.348","volume":"16","author":"PJ Bekker","year":"2001","unstructured":"Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res, 16(2): 348\u2013360, 2001","journal-title":"J Bone Miner Res"},{"issue":"6","key":"818_CR15","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1530\/eje.0.1450681","volume":"145","author":"LC Hofbauer","year":"2001","unstructured":"Hofbauer LC, Schoppet M. Serum measurement of osteoprotegerin \u2013 clinical relevance and potential applications. Eur J Endocrinol, 145(6): 681\u2013683, 2001","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"818_CR16","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1210\/jc.2005-0794","volume":"90","author":"A Rogers","year":"2005","unstructured":"Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab, 90(11): 6323\u20136331, 2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"5 Pt 1","key":"818_CR17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1262-3636(07)70303-8","volume":"32","author":"O Alexopoulou","year":"2006","unstructured":"Alexopoulou O, Jamart J, Devogelaer JP, et al. Bone density and markers of bone remodeling in type 1 male diabetic patients. Diabetes Metab, 32(5 Pt 1): 453\u2013458, 2006","journal-title":"Diabetes Metab"},{"issue":"2","key":"818_CR18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF03345584","volume":"31","author":"H Uemura","year":"2008","unstructured":"Uemura H, Yasui T, Miyatani Y, et al. Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in post-menopausal women. J Endocrinol Invest, 31(2): 163\u2013168, 2008","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"818_CR19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00198-007-0440-y","volume":"19","author":"HY Zhao","year":"2008","unstructured":"Zhao HY, Liu JM, Ning G, et al. Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women. Osteoporos Int, 19(2): 221\u2013226, 2008","journal-title":"Osteoporos Int"},{"issue":"6","key":"818_CR20","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S8756-3282(03)00090-5","volume":"32","author":"S Kudlacek","year":"2003","unstructured":"Kudlacek S, Schneider B, Woloszczuk W, et al. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone, 32(6): 681\u2013686, 2003","journal-title":"Bone"},{"issue":"3","key":"818_CR21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/13685530008500340","volume":"3","author":"S Kudlacek","year":"2000","unstructured":"Kudlacek S, Willvonseder R, Stohlawetz P, et al. Immunology and aging. Aging Male, 3(3): 137\u2013142, 2000","journal-title":"Aging Male"},{"issue":"5","key":"818_CR22","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/gme.0b013e3181a181b8","volume":"16","author":"I Nabipour","year":"2009","unstructured":"Nabipour I, Larijani B, Vahdat K, et al. Relationships among serum receptor of nuclear factor-kappa B ligand, osteoprotegerin, high- sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory. Menopause, 16(5): 950\u2013955, 2009","journal-title":"Menopause"},{"issue":"9","key":"818_CR23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF03040334","volume":"115","author":"A Fahrleitner-Pammer","year":"2003","unstructured":"Fahrleitner-Pammer A, Dobnig H, Piswanger-Soelkner C, et al. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. Wien Klin Wochenschr, 115(9): 291\u2013297, 2003","journal-title":"Wien Klin Wochenschr"},{"issue":"4","key":"818_CR24","first-page":"409","volume":"41","author":"D Grigorie","year":"2003","unstructured":"Grigorie D, Neacsu E, Marinescu M, Popa O. Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. Rom J Intern Med, 41(4): 409\u2013415, 2003","journal-title":"Rom J Intern Med"},{"issue":"11","key":"818_CR25","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1007\/s00198-005-1844-1","volume":"16","author":"P Mezquita-Raya","year":"2005","unstructured":"Mezquita-Raya P, de la Higuera M, Garcia DF, Alonso G, et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int, 16(11): 1368\u20131374, 2005","journal-title":"Osteoporos Int"},{"issue":"1","key":"818_CR26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.metabol.2004.08.005","volume":"54","author":"ES Oh","year":"2005","unstructured":"Oh ES, Rhee EJ, Oh KW, et al. Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. Metabolism, 54(1): 49\u201354, 2005","journal-title":"Metabolism"},{"issue":"1","key":"818_CR27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2265.2004.02179.x","volume":"62","author":"KW Oh","year":"2005","unstructured":"Oh KW, Rhee EJ, Lee WY, et al. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. Clin Endocrinol (Oxf), 62(1): 92\u201398, 2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"818_CR28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.bone.2004.12.015","volume":"36","author":"B Abrahamsen","year":"2005","unstructured":"Abrahamsen B, Hjelmborg JV, Kostenuik P, et al. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. Bone, 36(4): 727\u2013735, 2005","journal-title":"Bone"},{"issue":"1","key":"818_CR29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00774-006-0728-6","volume":"25","author":"NG Angelopoulos","year":"2007","unstructured":"Angelopoulos NG, Goula A, Katounda E, et al. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major. J Bone Miner Metab, 25(1): 60\u201367, 2007","journal-title":"J Bone Miner Metab"},{"issue":"12","key":"818_CR30","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1007\/s10067-007-0639-5","volume":"26","author":"P Oelzner","year":"2007","unstructured":"Oelzner P, Franke S, Lehmann G, et al. Soluble receptor activator of NFkappaB-ligand and osteoprotegerin in rheumatoid arthritis \u2013 relationship with bone mineral density, disease activity and bone turnover. Clin Rheumatol, 26(12): 2127\u20132135, 2007","journal-title":"Clin Rheumatol"},{"issue":"1","key":"818_CR31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF03347395","volume":"30","author":"M Gugatschka","year":"2007","unstructured":"Gugatschka M, Hoeller A, Fahrleitner-Pammer A, et al. Calcium supply, bone mineral density and genetically defined lactose maldigestion in a cohort of elderly men. J Endocrinol Invest, 30(1): 46\u201351, 2007","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"818_CR32","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00198-003-1550-9","volume":"15","author":"P Pennisi","year":"2004","unstructured":"Pennisi P, Signorelli SS, Riccobene S, et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int, 15(5): 389\u2013395, 2004","journal-title":"Osteoporos Int"},{"issue":"7","key":"818_CR33","first-page":"3162","volume":"86","author":"P Szulc","year":"2001","unstructured":"Szulc P, Hofbauer LC, Heufelder AE, et al. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab, 86(7): 3162\u20133165, 2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"818_CR34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1530\/EJE-06-0753","volume":"156","author":"A Stern","year":"2007","unstructured":"Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol, 156(5): 555\u2013562, 2007","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"818_CR35","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ajkd.2003.07.005","volume":"42","author":"G Coen","year":"2003","unstructured":"Coen G, Ballanti P, Fischer MS, et al. Serum leptin in dialysis renal osteodystrophy. Am J Kidney Dis, 42(5): 1036\u20131042, 2003","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"818_CR36","first-page":"7","volume":"58","author":"M Holecki","year":"2007","unstructured":"Holecki M, Zahorska-Markiewicz B, Janowska J, et al. Osteoprotegerin \u2013 does it play a protective role in the pathogenesis of bone loss in obese perimenopausal women? Endokrynol Pol 58(1): 7\u201310, 2007","journal-title":"Endokrynol Pol"},{"issue":"6","key":"818_CR37","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1507\/endocrj.K07-034","volume":"54","author":"R Ohwada","year":"2007","unstructured":"Ohwada R, Hotta M, Sato K, et al. The relationship between serum levels of estradiol and osteoprotegerin in patients with anorexia nervosa. Endocr J, 54(6): 953\u2013959, 2007","journal-title":"Endocr J"},{"issue":"4","key":"818_CR38","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0168-8278(02)00435-X","volume":"38","author":"F Szalay","year":"2003","unstructured":"Szalay F, Hegedus D, Lakatos PL, et al. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol, 38(4): 395\u2013400, 2003","journal-title":"J Hepatol"},{"issue":"5","key":"818_CR39","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00198-005-0035-4","volume":"17","author":"H Dobnig","year":"2006","unstructured":"Dobnig H, Hofbauer LC, Viereck V, et al. Changes in the RANK ligand\/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int, 17(5): 693\u2013703, 2006","journal-title":"Osteoporos Int"},{"issue":"15\u201316","key":"818_CR40","first-page":"717","volume":"114","author":"A Fahrleitner","year":"2002","unstructured":"Fahrleitner A, Prenner G, Kniepeiss D, et al. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status. Wien Klin Wochenschr, 114(15\u201316): 717\u2013724, 2002","journal-title":"Wien Klin Wochenschr"},{"issue":"2","key":"818_CR41","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1478-3231.2005.01073.x","volume":"25","author":"E Fabrega","year":"2005","unstructured":"Fabrega E, Orive A, Garcia-Suarez C, et al. Osteoprotegerin and RANKL in alcoholic liver cirrhosis. Liver Int, 25(2): 305\u2013310, 2005","journal-title":"Liver Int"},{"issue":"6","key":"818_CR42","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-2006-944548","volume":"38","author":"CE Fiore","year":"2006","unstructured":"Fiore CE, Pennisi P, Ferro G, et al. Altered osteoprotegerin\/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet. Horm Metab Res, 38(6): 417\u2013422, 2006","journal-title":"Horm Metab Res"},{"issue":"10","key":"818_CR43","first-page":"1118","volume":"43","author":"M Herrmann","year":"2005","unstructured":"Herrmann M, Kraenzlin M, Pape G, et al. Relation between homocysteine and biochemical bone turnover markers and bone mineral density in peri- and post-menopausal women. Clin Chem Lab Med, 43(10): 1118\u20131123, 2005","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"818_CR44","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1478-3231.2007.01448.x","volume":"27","author":"A Monegal","year":"2007","unstructured":"Monegal A, Navasa M, Peris P, et al. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease. Liver Int, 27(4): 492\u2013497, 2007","journal-title":"Liver Int"},{"issue":"3","key":"818_CR45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000196280","volume":"55","author":"Y Chiba","year":"2009","unstructured":"Chiba Y, Onouchi T, Ikeda T, et al. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women. Gerontology, 55(3): 275\u2013280, 2009","journal-title":"Gerontology"},{"issue":"22","key":"818_CR46","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1097\/00029330-200711020-00015","volume":"120","author":"Y Dai","year":"2007","unstructured":"Dai Y, Shen L. Relationships between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women. Chin Med J (Engl), 120(22): 2017\u20132021, 2007","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"818_CR47","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S8756-3282(02)00926-2","volume":"32","author":"A Fahrleitner","year":"2003","unstructured":"Fahrleitner A, Prenner G, Leb G, et al. Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. Bone, 32(1): 96\u2013106, 2003","journal-title":"Bone"},{"issue":"3","key":"818_CR48","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11914-996-0031-4","volume":"4","author":"CN Bernstein","year":"2006","unstructured":"Bernstein CN. Inflammatory bowel diseases as secondary causes of osteoporosis. Curr Osteoporos Rep, 4(3): 116\u2013123, 2006","journal-title":"Curr Osteoporos Rep"},{"issue":"6","key":"818_CR49","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jhep.2005.05.034","volume":"43","author":"AR Moschen","year":"2005","unstructured":"Moschen AR, Kaser A, Stadlmann S, et al. The RANKL\/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol, 43(6): 973\u2013983, 2005","journal-title":"J Hepatol"},{"issue":"3","key":"818_CR50","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1530\/eje.0.1500305","volume":"150","author":"S Trofimov","year":"2004","unstructured":"Trofimov S, Pantsulaia I, Kobyliansky E, Livshits G. Circulating levels of receptor activator of nuclear factor-kappaB ligand\/osteoprotegerin\/macrophage-colony stimulating factor in a presumably healthy human population. Eur J Endocrinol, 150(3): 305\u2013311, 2004","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"818_CR51","doi-asserted-by":"crossref","first-page":"652","DOI":"10.5414\/CNP71652","volume":"71","author":"A Fahrleitner-Pammer","year":"2009","unstructured":"Fahrleitner-Pammer A, Dobnig H, Dimai HP, et al. The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure. Clin Nephrol, 71(6): 652\u2013659, 2009","journal-title":"Clin Nephrol"},{"issue":"9","key":"818_CR52","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jama.291.9.1108","volume":"291","author":"G Schett","year":"2004","unstructured":"Schett G, Kiechl S, Redlich K, et al. Soluble RANKL and risk of nontraumatic fracture. JAMA, 291(9): 1108\u20131113, 2004","journal-title":"JAMA"},{"issue":"8","key":"818_CR53","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.3899\/jrheum.081337","volume":"36","author":"EK Li","year":"2009","unstructured":"Li EK, Tam LS, Griffith JF, et al. High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus. J Rheumatol, 36(8): 1646\u20131652, 2009","journal-title":"J Rheumatol"},{"issue":"1","key":"818_CR54","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.maturitas.2006.05.007","volume":"56","author":"EM Messalli","year":"2007","unstructured":"Messalli EM, Mainini G, Scaffa C, et al. Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. Maturitas, 56(1): 38\u201344, 2007","journal-title":"Maturitas"},{"issue":"5","key":"818_CR55","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/BF03346385","volume":"31","author":"D Fernandez-Garcia","year":"2008","unstructured":"Fernandez-Garcia D, Munoz-Torres M, Mezquita-Raya P, et al. Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis. J Endocrinol Invest, 31(5): 416\u2013421, 2008","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"818_CR56","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00774-009-0055-9","volume":"27","author":"U Dundar","year":"2009","unstructured":"Dundar U, Kavuncu V, Ciftci IH, et al. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study. J Bone Miner Metab, 27(4): 464\u2013470, 2009","journal-title":"J Bone Miner Metab"},{"issue":"7","key":"818_CR57","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1210\/jc.2003-032066","volume":"89","author":"EC Buxton","year":"2004","unstructured":"Buxton EC, Yao W, Lane NE. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1\u201334). J Clin Endocrinol Metab, 89(7): 3332\u20133336, 2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"818_CR58","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1530\/EJE-07-0528","volume":"158","author":"AD Anastasilakis","year":"2008","unstructured":"Anastasilakis AD, Goulis DG, Polyzos SA, et al. Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide. Eur J Endocrinol, 158(3): 411\u2013415, 2008","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"818_CR59","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1055\/s-2008-1046787","volume":"40","author":"AD Anastasilakis","year":"2008","unstructured":"Anastasilakis AD, Goulis DG, Polyzos SA, et al. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial. Horm Metab Res, 40(4): 281\u2013285, 2008","journal-title":"Horm Metab Res"},{"issue":"1","key":"818_CR60","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/gme.0b013e3181ac0cc1","volume":"17","author":"R Reyes-Garcia","year":"2010","unstructured":"Reyes-Garcia R, Munoz-Torres M, Garcia DF, et al. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis. Menopause, 17(1): 140\u2013144, 2010","journal-title":"Menopause"},{"issue":"11","key":"818_CR61","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/ibd.20234","volume":"13","author":"P Miheller","year":"2007","unstructured":"Miheller P, Muzes G, Racz K, et al. Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy. Inflamm Bowel Dis, 13(11): 1379\u20131384, 2007","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"818_CR62","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/ard.2005.044198","volume":"65","author":"M Vis","year":"2006","unstructured":"Vis M, Havaardsholm EA, Haugeberg G, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis, 65(11): 1495\u20131499, 2006","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"818_CR63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00223-007-9041-1","volume":"81","author":"R Cibulka","year":"2007","unstructured":"Cibulka R, Racek J, Pikner R, et al. Effect of L-carnitine supplementation on secondary hyperparathyroidism and bone metabolism in hemodialyzed patients. Calcif Tissue Int, 81(2): 99\u2013106, 2007","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"818_CR64","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ndt\/17.2.233","volume":"17","author":"G Coen","year":"2002","unstructured":"Coen G, Ballanti P, Balducci A, et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant, 17(2): 233\u2013238, 2002","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 10","key":"818_CR65","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ndt\/17.suppl_10.2","volume":"17","author":"M Fukagawa","year":"2002","unstructured":"Fukagawa M, Kazama JJ, Kurokawa K. Renal osteodystrophy and secondary hyperparathyroidism. Nephrol Dial Transplant, 17(Suppl 10): 2\u20135, 2002","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"818_CR66","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF03346365","volume":"31","author":"C Santori","year":"2008","unstructured":"Santori C, Ceccanti M, Diacinti D, et al. Skeletal turnover, bone mineral density, and fractures in male chronic abusers of alcohol. J Endocrinol Invest, 31(4): 321\u2013326, 2008","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"818_CR67","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1210\/jc.2009-0835","volume":"94","author":"JL Gonzalez-Calvin","year":"2009","unstructured":"Gonzalez-Calvin JL, Mundi JL, Casado-Caballero FJ, et al. Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis. J Clin Endocrinol Metab, 94(12): 4844\u20134850, 2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"818_CR68","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1359\/jbmr.2002.17.11.1961","volume":"17","author":"D Hegedus","year":"2002","unstructured":"Hegedus D, Ferencz V, Lakatos PL, et al. Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. J Bone Miner Res, 17(11): 1961\u20131967, 2002","journal-title":"J Bone Miner Res"},{"issue":"3","key":"818_CR69","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1399-0012.2006.00497.x","volume":"20","author":"E Fabrega","year":"2006","unstructured":"Fabrega E, Orive A, Garcia-Unzueta M, et al. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation. Clin Transplant, 20(3): 383\u2013388, 2006","journal-title":"Clin Transplant"},{"issue":"1\u20132","key":"818_CR70","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0378-1119(97)00509-X","volume":"204","author":"KB Tan","year":"1997","unstructured":"Tan KB, Harrop J, Reddy M, et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene, 204(1\u20132): 35\u201346, 1997","journal-title":"Gene"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-010-0818-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10354-010-0818-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-010-0818-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T16:03:53Z","timestamp":1559145833000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10354-010-0818-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,16]]},"references-count":70,"journal-issue":{"issue":"17-18","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["818"],"URL":"https:\/\/doi.org\/10.1007\/s10354-010-0818-x","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,16]]}}}